+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Solid Tumor"

Pipeline of CD73 Inhibitors - Product Thumbnail Image

Pipeline of CD73 Inhibitors

  • Report
  • December 2025
  • Global
From
Pipeline of EpCAM-Targeted Immunotherapies - Product Thumbnail Image

Pipeline of EpCAM-Targeted Immunotherapies

  • Report
  • December 2025
  • Global
From
Pipeline of Nectin-4-Targeted Immunotherapies - Product Thumbnail Image

Pipeline of Nectin-4-Targeted Immunotherapies

  • Report
  • December 2025
  • Global
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

The Solid Tumor market within the context of Oncology is a highly competitive and rapidly evolving field. It is focused on the development of treatments for solid tumors, which are malignant tumors that form in the body's organs and tissues. These tumors can be caused by a variety of factors, including genetic mutations, environmental exposures, and lifestyle choices. Treatment options for solid tumors include surgery, chemotherapy, radiation therapy, and targeted therapies. The Solid Tumor market is driven by the increasing prevalence of cancer, advances in technology, and the development of new treatments. Companies in this market are focused on developing innovative treatments and therapies to improve patient outcomes. Examples of companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more